*Optimal dilutions/concentrations should be determined by the researcher.
|0.5 - 2 μg/mL
Not tested in other applications.
Human Small Intestine Tissue Lysate(GTX27923) , Human Small Intestine Tissue Slide
PBS with 0.02% sodium azide.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
1 mg/ml (Please refer to the vial label for the specific concentration.)
AATF antibody was raised against a 12 amino acid synthetic peptide from near the carboxy terminus of human AATF.The immunogen is located within the last 50 amino acids of AATF.
Purified by affinity chromatography
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
apoptosis antagonizing transcription factor , BFR2 , CHE-1 , CHE1 , DED
AATF (apoptosis antagonizing transcription factor) was initially discovered as an interaction partner of ZIP kinase (ZIPK) (1), a member of death-associated protein (DAP) kinase family of pro-apoptotic serine/threonine kinases (2). AATF is a phosphoprotein containing an acidic region and a putative leucine zipper domain and nuclear localization signal, features which are typical of transcription factors. AATF inhibits the ZIPK-mediated pro-apoptotic pathway and may activate other anti-apoptotic pathways (3). Recently, it has also been shown to protect neural cells against oxidative damage induced by amyloid b-peptide and to inhibit aberrant production of the b-peptide by interacting with Par-4 (prostate apoptosis response-4), another pro-apoptotic leucine zipper protein that is associated with neuronal degeneration in Alzheimer’s disease (AD) (4,5), suggesting that AATF may have potential therapeutic applications in both familial and sporadic forms of AD.